Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Akeso Biopharma of Zhongshan Closes $45 Million B Round

publication date: Aug 29, 2017

Akeso Biopharma, a Zhongshan antibody company, closed a $45 million B round, led by the GTJA Investment Group. Founded in 2012, Akeso subjects its antibody candidates to 3D analysis simulations. It says the process improves the antibody's affinity for a target by a factor of up to 100 times. Two years ago, Merck/MSD agreed to a $200 million package of milestones in return for global rights to an Akeso immune checkpoint antibody. Akeso is currently developing 25 research projects involving drugs for oncology, inflammation, autoimmune and cardiovascular diseases. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital